nach oben

Breast Cancer Research and Treatment

Erschienen in:

23.05.2020 | Clinical trial

Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer

verfasst von: Su Min Ha, Jung Min Chang, Su Hyun Lee, Eun Sil Kim, Soo-Yeon Kim, Nariya Cho, Woo Kyung Moon

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Diffusion-weighted magnetic resonance imaging (DW-MRI) offers unenhanced method to detect breast cancer without cost and safety concerns associated with dynamic contrast-enhanced (DCE) MRI. Our purpose was to evaluate the performance of DW-MRI at 3.0T in detection of clinically and mammographically occult contralateral breast cancer in patients with unilateral breast cancer.

Methods

Between 2017 and 2018, 1130 patients (mean age 53.3 years; range 26–84 years) with newly diagnosed unilateral breast cancer who underwent breast MRI and had no abnormalities on clinical and mammographic examinations of contralateral breast were included. Three experienced radiologists independently reviewed DW-MRI (b = 0 and 1000 s/mm²) and DCE-MRI and assigned a BI-RADS category. Using histopathology or 1-year clinical follow-up, performance measures of DW-MRI were compared with DCE-MRI.

Results

A total of 21 (1.9%, 21/1130) cancers were identified (12 ductal carcinoma in situ and 9 invasive ductal carcinoma; mean invasive tumor size, 8.0 mm) in the contralateral breast. Cancer detection rate of DW-MRI was 13–15 with mean of 14 per 1000 examinations (95% confidence interval [CI] 9–23 per 1000 examinations), which was lower than that of DCE-MRI (18–19 with mean of 18 per 1000 examinations, P = 0.01). A lower abnormal interpretation rate (14.0% versus 17.0%, respectively, P < 0.001) with higher specificity (87.3% versus 84.6%, respectively, P < 0.001) but lower sensitivity (77.8% versus 96.8%, respectively, P < 0.001) was noted for DW-MRI compared to DCE-MRI.

Conclusions

DW-MRI at 3.0T has the potential as a cost-effective tool for evaluation of contralateral breast in women with newly diagnosed breast cancer.

Nur mit Berechtigung zugänglich

Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R, American Cancer Society (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314:1599–1614. https://doi.org/10.1001/jama.2015.12783 CrossRefPubMedPubMedCentral

Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K, ACRIN 6666 Investigators (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299:2151–2163. https://doi.org/10.1001/jama.299.18.2151 CrossRefPubMedPubMedCentral

Mainiero MB, Moy L, Baron P, Didwania AD, diFlorio RM, Green ED, Heller SL, Holbrook AI, Lee SJ, Lewin AA, Lourenco AP, Nance KJ, Niell BL, Slanetz PJ, Stuckey AR, Vincoff NS, Weinstein SP, Yepes MM, Newell MS (2017) ACR appropriateness criteria® breast cancer screening. J Am Coll Radiol 14:S383–S390. https://doi.org/10.1016/j.jacr.2017.08.044 CrossRefPubMed

Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon JM, Warren RM, Ciatto S (2009) Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 27:5640–5649. https://doi.org/10.1200/jco.2008.21.5756 CrossRefPubMed

Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD, ACRIN Trial 6667 Investigators Group (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356:1295–1303. https://doi.org/10.1056/NEJMoa065447 CrossRefPubMed

Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB (2014) Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 32:2304–2310. https://doi.org/10.1200/JCO.2013.52.5386 CrossRefPubMed

Gweon HM, Cho N, Han W, Yi A, Moon HG, Noh DY, Moon WK (2014) Breast MR imaging screening in women with a history of breast conservation therapy. Radiology 272:366–373. https://doi.org/10.1148/radiol.14131893 CrossRefPubMed

Lehman CD, Lee JM, DeMartini WB, Hippe DS, Rendi MH, Kalish G, Porter P, Gralow J, Partridge SC (2016) Screening MRI in women With a personal history of breast cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv349 CrossRefPubMed

Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 15:408–414. https://doi.org/10.1016/j.jacr.2017.11.034 CrossRefPubMed

10.

Houssami N, Hayes DF (2009) Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 59:290–302. https://doi.org/10.3322/caac.20028 CrossRefPubMed

11.

Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356:1295–1303. https://doi.org/10.1056/NEJMoa065447 CrossRefPubMed

12.

Morrow M, Waters J, Morris E (2011) MRI for breast cancer screening, diagnosis, and treatment. Lancet 378:1804–1811. https://doi.org/10.1016/s0140-6736(11)61350-0 CrossRefPubMed

13.

Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Kobrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316. https://doi.org/10.1016/j.ejca.2010.02.015 CrossRefPubMed

14.

Lee JM, Ichikawa L, Valencia E, Miglioretti DL, Wernli K, Buist DSM, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD (2017) Performance Benchmarks for Screening Breast MR Imaging in Community Practice. Radiology 285:44–52. https://doi.org/10.1148/radiol.2017162033 CrossRefPubMedPubMedCentral

15.

Niell BL, Gavenonis SC, Motazedi T, Chubiz JC, Halpern EP, Rafferty EA, Lee JM (2014) Auditing a breast MRI practice: performance measures for screening and diagnostic breast MRI. J Am Coll Radiol 11:883–889. https://doi.org/10.1016/j.jacr.2014.02.003 CrossRefPubMedPubMedCentral

16.

Strigel RM, Rollenhagen J, Burnside ES, Elezaby M, Fowler AM, Kelcz F, Salkowski L, DeMartini WB (2017) Screening breast MRI outcomes in routine clinical practice: comparison to BI-RADS benchmarks. Acad Radiol 24:411–417. https://doi.org/10.1016/j.acra.2016.10.014 CrossRefPubMed

17.

Houssami N, Turner RM, Morrow M (2017) Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat 165:273–283. https://doi.org/10.1007/s10549-017-4324-3 CrossRefPubMedPubMedCentral

18.

Leithner D, Moy L, Morris EA, Marino MA, Helbich TH, Pinker K (2019) Abbreviated MRI of the breast: does it provide value? J Magn Reson Imaging 49:e85–e100. https://doi.org/10.1002/jmri.26291 CrossRefPubMed

19.

Amornsiripanitch N, Bickelhaupt S, Shin HJ, Dang M, Rahbar H, Pinker K, Partridge SC (2019) Diffusion-weighted MRI for unenhanced breast cancer screening. Radiology 293:504–520. https://doi.org/10.1148/radiol.2019182789 CrossRefPubMed

20.

Partridge SC, McDonald ES (2013) Diffusion weighted magnetic resonance imaging of the breast: protocol optimization, interpretation, and clinical applications. Magn Reson Imaging Clin N Am 21:601–624. https://doi.org/10.1016/j.mric.2013.04.007 CrossRefPubMedPubMedCentral

21.

Galban CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD (2015) Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. PLoS ONE 10:e0122151. https://doi.org/10.1371/journal.pone.0122151 CrossRefPubMedPubMedCentral

22.

Baxter GC, Graves MJ, Gilbert FJ, Patterson AJ (2019) A meta-analysis of the diagnostic performance of diffusion MRI for breast lesion characterization. Radiology 291:632–641. https://doi.org/10.1148/radiol.2019182510 CrossRefPubMed

23.

Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K, Kuranami M, Watanabe M, Hayakawa K (2005) ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 4:35–42. https://doi.org/10.2463/mrms.4.35 CrossRefPubMed

24.

Zhang L, Tang M, Min Z, Lu J, Lei X, Zhang X (2016) Accuracy of combined dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging for breast cancer detection: a meta-analysis. Acta Radiol 57:651–660. https://doi.org/10.1177/0284185115597265 CrossRefPubMed

25.

Rahbar H, Zhang Z, Chenevert TL, Romanoff J, Kitsch AE, Hanna LG, Harvey SM, Moy L, DeMartini WB, Dogan B, Yang WT, Wang LC, Joe BN, Oh KY, Neal CH, McDonald ES, Schnall MD, Lehman CD, Comstock CE, Partridge SC (2019) Utility of diffusion-weighted imaging to decrease unnecessary biopsies prompted by breast MRI: a trial of the ECOG-ACRIN Cancer Research Group (A6702). Clin Cancer Res 25:1756–1765. https://doi.org/10.1158/1078-0432.CCR-18-2967 CrossRefPubMedPubMedCentral

26.

Baltzer PA, Benndorf M, Dietzel M, Gajda M, Camara O, Kaiser WA (2010) Sensitivity and specificity of unenhanced MR mammography (DWI combined with T2-weighted TSE imaging, ueMRM) for the differentiation of mass lesions. Eur Radiol 20:1101–1110. https://doi.org/10.1007/s00330-009-1654-5 CrossRefPubMed

27.

Bickelhaupt S, Laun FB, Tesdorff J, Lederer W, Daniel H, Stieber A, Delorme S, Schlemmer HP (2016) Fast and noninvasive characterization of suspicious lesions detected at breast cancer X-Ray screening: capability of diffusion-weighted MR imaging with MIPs. Radiology 278:689–697. https://doi.org/10.1148/radiol.2015150425 CrossRefPubMed

28.

McDonald ES, Hammersley JA, Chou SH, Rahbar H, Scheel JR, Lee CI, Liu CL, Lehman CD, Partridge SC (2016) Performance of DWI as a rapid unenhanced technique for detecting mammographically occult breast cancer in elevated-risk women with dense breasts. AJR Am J Roentgenol 207:205–216. https://doi.org/10.2214/AJR.15.15873 CrossRefPubMed

29.

Shin HJ, Chae EY, Choi WJ, Ha SM, Park JY, Shin KC, Cha JH, Kim HH (2016) Diagnostic performance of fused diffusion-weighted imaging using unenhanced or postcontrast T1-weighted MR imaging in patients with breast cancer. Medicine (Baltimore) 95:e3502. https://doi.org/10.1097/MD.0000000000003502 CrossRef

30.

Telegrafo M, Rella L, Stabile Ianora AA, Angelelli G, Moschetta M (2015) Unenhanced breast MRI (STIR, T2-weighted TSE, DWIBS): an accurate and alternative strategy for detecting and differentiating breast lesions. Magn Reson Imaging 33:951–955. https://doi.org/10.1016/j.mri.2015.06.002 CrossRefPubMed

31.

Trimboli RM, Verardi N, Cartia F, Carbonaro LA, Sardanelli F (2014) Breast cancer detection using double reading of unenhanced MRI including T1-weighted, T2-weighted STIR, and diffusion-weighted imaging: a proof of concept study. AJR Am J Roentgenol 203:674–681. https://doi.org/10.2214/AJR.13.11816 CrossRefPubMed

32.

Yabuuchi H, Matsuo Y, Sunami S, Kamitani T, Kawanami S, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H (2011) Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging. Eur Radiol 21:11–17. https://doi.org/10.1007/s00330-010-1890-8 CrossRefPubMed

33.

Kang JW, Shin HJ, Shin KC, Chae EY, Choi WJ, Cha JH, Kim HH (2017) Unenhanced magnetic resonance screening using fused diffusion-weighted imaging and maximum-intensity projection in patients with a personal history of breast cancer: role of fused DWI for postoperative screening. Breast Cancer Res Treat 165:119–128. https://doi.org/10.1007/s10549-017-4322-5 CrossRefPubMed

34.

Bogner W, Pinker K, Zaric O, Baltzer P, Minarikova L, Porter D, Bago-Horvath Z, Dubsky P, Helbich TH, Trattnig S, Gruber S (2015) Bilateral diffusion-weighted MR imaging of breast tumors with submillimeter resolution using readout-segmented echo-planar imaging at 7 T. Radiology 274:74–84. https://doi.org/10.1148/radiol.14132340 CrossRefPubMed

35.

Bogner W, Pinker-Domenig K, Bickel H, Chmelik M, Weber M, Helbich TH, Trattnig S, Gruber S (2012) Readout-segmented echo-planar imaging improves the diagnostic performance of diffusion-weighted MR breast examinations at 3.0 T. Radiology 263:64–76. https://doi.org/10.1148/radiol.12111494 CrossRefPubMed

36.

Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD (2010) Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. J Magn Reson Imaging 31:562–570. https://doi.org/10.1002/jmri.22078 CrossRefPubMed

37.

Bogner W, Gruber S, Pinker K, Grabner G, Stadlbauer A, Weber M, Moser E, Helbich TH, Trattnig S (2009) Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? Radiology 253:341–351. https://doi.org/10.1148/radiol.2532081718 CrossRefPubMed

38.

Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M (2007) Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci 6:21–27CrossRef

39.

Radovic N, Ivanac G, Divjak E, Biondic I, Bulum A, Brkljacic B (2019) Evaluation of breast cancer morphology using diffusion-weighted and dynamic contrast-enhanced MRI: intermethod and interobserver agreement. J Magn Reson Imaging 49:1381–1390. https://doi.org/10.1002/jmri.26332 CrossRefPubMed

40.

D'Orsi CJ (2013) ACR BI-RADS atlas : breast imaging reporting and data system. American College of Radiology, Reston (VA)

41.

Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Bohm-Velez M, Mahoney MC, Evans WP 3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G, ACRIN 6666 Investigators (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404. https://doi.org/10.1001/jama.2012.388 CrossRefPubMedPubMedCentral

42.

Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232. https://doi.org/10.1148/radiol.2015142690 CrossRefPubMed

43.

Cho N, Han W, Han BK, Bae MS, Ko ES, Nam SJ, Chae EY, Lee JW, Kim SH, Kang BJ, Song BJ, Kim EK, Moon HJ, Kim SI, Kim SM, Kang E, Choi Y, Kim HH, Moon WK (2017) Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol 3:1495–1502. https://doi.org/10.1001/jamaoncol.2017.1256 CrossRefPubMedPubMedCentral

44.

Kazama T, Kuroki Y, Kikuchi M, Sato Y, Nagashima T, Miyazawa Y, Sakakibara M, Kaneoya K, Makimoto Y, Hashimoto H, Motoori K, Takano H (2012) Diffusion-weighted MRI as an adjunct to mammography in women under 50 years of age: an initial study. J Magn Reson Imaging 36:139–144. https://doi.org/10.1002/jmri.23626 CrossRefPubMed

45.

Amornsiripanitch N, Rahbar H, Kitsch AE, Lam DL, Weitzel B, Partridge SC (2018) Visibility of mammographically occult breast cancer on diffusion-weighted MRI versus ultrasound. Clin Imaging 49:37–43. https://doi.org/10.1016/j.clinimag.2017.10.017 CrossRefPubMed

46.

Han X, Li J, Wang X (2017) Comparison and optimization of 3.0 T breast images quality of diffusion-weighted imaging with multiple b-values. Acad Radiol 24:418–425. https://doi.org/10.1016/j.acra.2016.11.006 CrossRefPubMed

47.

Tamura T, Murakami S, Naito K, Yamada T, Fujimoto T, Kikkawa T (2014) Investigation of the optimal b-value to detect breast tumors with diffusion weighted imaging by 1.5-T MRI. Cancer Imaging 14:11. https://doi.org/10.1186/1470-7330-14-11 CrossRefPubMedPubMedCentral

48.

Pinker K, Moy L, Sutton EJ, Mann RM, Weber M, Thakur SB, Jochelson MS, Bago-Horvath Z, Morris EA, Baltzer PA, Helbich TH (2018) Diffusion-weighted imaging with apparent diffusion coefficient mapping for breast cancer detection as a stand-alone parameter: comparison with dynamic contrast-enhanced and multiparametric magnetic resonance imaging. Invest Radiol 53:587–595. https://doi.org/10.1097/rli.0000000000000465 CrossRefPubMedPubMedCentral

49.

Bickel H, Pinker-Domenig K, Bogner W, Spick C, Bago-Horvath Z, Weber M, Helbich T, Baltzer P (2015) Quantitative apparent diffusion coefficient as a noninvasive imaging biomarker for the differentiation of invasive breast cancer and ductal carcinoma in situ. Invest Radiol 50:95–100. https://doi.org/10.1097/rli.0000000000000104 CrossRefPubMed

50.

Rahbar H, Partridge SC, Eby PR, Demartini WB, Gutierrez RL, Peacock S, Lehman CD (2011) Characterization of ductal carcinoma in situ on diffusion weighted breast MRI. Eur Radiol 21:2011–2019. https://doi.org/10.1007/s00330-011-2140-4 CrossRefPubMed

51.

Iima M, Le Bihan D, Okumura R, Okada T, Fujimoto K, Kanao S, Tanaka S, Fujimoto M, Sakashita H, Togashi K (2011) Apparent diffusion coefficient as an MR imaging biomarker of low-risk ductal carcinoma in situ: a pilot study. Radiology 260:364–372. https://doi.org/10.1148/radiol.11101892 CrossRefPubMed

52.

Youk JH, Son EJ, Chung J, Kim JA, Kim EK (2012) Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol 22:1724–1734. https://doi.org/10.1007/s00330-012-2425-2 CrossRefPubMed

53.

Avendano D, Marino MA, Leithner D, Thakur S, Bernard-Davila B, Martinez DF, Helbich TH, Morris EA, Jochelson MS, Baltzer PAT, Clauser P, Kapetas P, Pinker K (2019) Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI. Breast Cancer Res 21:136. https://doi.org/10.1186/s13058-019-1208-y CrossRefPubMedPubMedCentral

54.

Iima M, Partridge SC, Le Bihan D (2020) Six DWI questions you always wanted to know but were afraid to ask: clinical relevance for breast diffusion MRI. Eur Radiol. https://doi.org/10.1007/s00330-019-06648-0 CrossRefPubMed

55.

Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team, and I-SPY 2 TRIAL Investigators (2019) Test-retest repeatability and reproducibility of ADC measures by breast DWI: results from the ACRIN 6698 trial. J Magn Reson Imaging 49:1617–1628. https://doi.org/10.1002/jmri.26539 CrossRefPubMed

56.

Bickelhaupt S, Paech D, Laun FB, Steudle F, Kuder TA, Mlynarska A, Bach M, Lederer W, Teiner S, Schneider S, Ladd ME, Daniel H, Stieber A, Kopp-Schneider A, Delorme S, Schlemmer HP (2017) Maximum intensity breast diffusion MRI for BI-RADS 4 lesions detected on X-ray mammography. Clin Radiol 72:900. https://doi.org/10.1016/j.crad.2017.05.017 CrossRefPubMed

57.

Vourtsis A, Berg WA (2019) Breast density implications and supplemental screening. Eur Radiol 29:1762–1777. https://doi.org/10.1007/s00330-018-5668-8 CrossRefPubMed

58.

Marinovich ML, Hunter KE, Macaskill P, Houssami N (2018) Breast cancer screening using tomosynthesis or mammography: a meta-analysis of cancer detection and recall. J Natl Cancer Inst 110:942–949. https://doi.org/10.1093/jnci/djy121 CrossRefPubMed

59.

ClinicalTrials.gov (2019) Breast cancer screening with diffusion-weighted MRI in women at high risk for breast cancer. https://clinicaltrials.gov/ct2/show/NCT03835897. Accessed 16 Jan 2020

Titel: Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer
verfasst von: Su Min Ha
Jung Min Chang
Su Hyun Lee
Eun Sil Kim
Soo-Yeon Kim
Nariya Cho
Woo Kyung Moon
Publikationsdatum: 23.05.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05697-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers

Utilization patterns and temporal trends of internal mammary nodal irradiation at a tertiary cancer center

Predictive risk factors of complications in different breast reconstruction methods

Stage-specific survival has improved for young breast cancer patients since 2000: but not equally

Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie